AGA Medical expands Amplatzer line
This article was originally published in The Gray Sheet
Firm launches Amplatzer Muscular VSD Occluder for closure of complex ventricular septal defects following PMA approval Sept. 7. The device, which is placed via a transcatheter procedure in patients at high risk for surgical closure, is the latest addition to AGA's Amplatzer line. Also available in the United States are the Amplatzer septal occluder for atrial septal defects, and the Amplatzer duct occluder for closure of patent ductus arteriosus defects. The firm also offers vascular plugs ("1The Gray Sheet" Sept. 3, 2007, p. 11)
You may also be interested in...
AGA Medical, a maker of minimally invasive devices to treat heart defects, is expanding its product portfolio further into the vascular space
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.